Dr. Paul Castella has experience in the evaluation, financing, licensing, formation and operation of biotechnology and medical technology companies. Paul specializes in financing and licensing strategies for technology start-ups, and in 2009, Paul co-founded Targeted Technology Fund I and II. Previously, Paul co-founded and served as the President and CFO of CardioSpectra, which was formed in late 2005 and acquired by Volcano Corporation (NASDAQ: VOLC) in December 2007. Other companies Paul has founded, co-founded, managed and financed include Xenotope Diagnostics, ViroXis Corporation, BiO2 Medical and Santalis Pharmacauticals.
Paul received his PhD in cell biology and genetics from Cornell University Medical College in Manhattan. He received his MBA from the University of Texas at San Antonio.
Alan Dean is a senior technology executive with over 30 years of experience in the technology development industry, and has been advisor to, and board member of, numerous technology companies, past and present. Alan is the co-founder and senior managing partner of the Targeted Technology Fund I and II. Previously, Alan was Managing Partner, Fund Operations, for Greer Capital Advisors in Birmingham, Alabama, with two-dozen portfolio companies and approximately $70 million under direct management. Prior to joining Greer Capitol Advisors, Alan was the Director of the Office of Technology Ventures at the University of Texas Health Science Center.
Alan earned his MBA from the University of Alabama at Birmingham and his BS in chemistry from the University of Alabama.
Ira is a corporate executive with over 35 years of decisive and successful financial management experience. His extensive finance and operations expertise, audit and procedural accounting background, along with extensive information systems and analytical skills have enabled him to meet corporate goals and produce results on time and within budget. Recently he has been mentoring startup companies in the Southeast including two additive manufacturing (3D printing) companies and has worked successfully with many startup and entreprenurial companies during his career. He also sits on several profit and non-profit boards having initiated several successful fund raising and corporate sponsorship programs.
Dr. Keith Champion has over 16 years of experience in both academic and industry science. Keith is focused on Gram-negative bacterial species with extensive experience in biochemistry, molecular biology and microbiology. Keith has been published in peer-reviewed journals and college textbooks, presented at international conferences and holds numerous patents in endotoxin-related technologies.
Keith received his PhD in biochemistry and molecular genetics and his BS in biology/chemistry from the University of Alabama at Birmingham.